SGLT-2: another study finding more amputations; are they being oversold??
a recent US veterans study compared SGLT-2 inhibitors with DPP-4 inhibitors in patients with diabetes and found increased peripheral artery disease (PAD) surgeries in those on the SGLT-2 inhibitors (see dm SGLT2 inc PAD DiabCare2025 in dropbox, or doi.org/10.2337/dc24-1546 Details: -- this was a retrospective cohort study of U.S. veterans with diabetes, aged at least 18yo who received care from the Veterans Health Administration from 1 October 2000 to 31 December 2021 -- data were linked to Medicare, Medicaid, and the National Death Index. -- included patients: new use of SGLT-2 or DPP-4 medications as an add-on to metformin, sulfonylurea, or insulin treatment alone or in combination -- these patients were evaluated for an association of these meds with a PAD surgical procedure for peripheral revascularization and amputation. -- the median age was 69 years, 95% male, HbA1c at baseline 8.4%...